Taiwanese electronics company Compal Electronics has expanded into the therapeutic medical device segment by introducing a new radiofrequency ablation (RFA) system called AblatePal.
The new RFA system is intended for use in coagulation and ablation of soft tissue during percutaneous and intraoperative procedures, including partial or complete ablation of non-resectable liver lesions.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Using the heat energy produced by electrical resistance when the current passes through the tissue, the ablation system will cauterise the tumour to enable tumour necrosis with its advanced cooling technology to avoid normal tissue damage.
This approach is expected to result in positive outcomes that can improve wound size and reduce the duration of hospitalisation for patients.
Compal president and CEO Martin Wong stated that the company has been actively engaged in the development of the medical and healthcare industry in recent years, with a focus high-end medical equipment.
Furthermore, the company has launched a Bilevel ventilator, dubbed BreathePal, to treat chronic obstructive pulmonary disease and respiratory insufficiency due to central and/or mixed apneas.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe Bilevel ventilator offers positive-pressure ventilation for adults suffering from respiratory insufficiency or failure.
It has an interchangeable battery and humidifier design and is designed for use in home or hospital settings.
Compal senior director Casper Chen said: “The company has established a demonstration and training centre to deepen medical exchanges with Malaysia.
“We will be exhibiting SE-Asian Healthcare & Pharma Show (SEACare) at booth no 4080 in KLCC from 19 to 21 April 2023.”
